- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
Leerink started coverage of Ariad Pharmaceuticals (ARIA) stock with an 'outperform' rating on Monday.
Ariad Pharma (ARIA) stock closed higher on Tuesday given renewed speculation that it might be a buyout target.
After putting in a bottom, Ariad Pharmaceuticals (ARIA) stock 'has risen like a Phoenix from the ashes,' said TheStreet's Chris Versace and Bob Lang.